Voyager, AbbVie to Collaborate on Parkinson's Disease Treatments, Voyager Up 21%

By Michael Dabaie

Voyager Therapeutics Inc. (VYGR) and AbbVie (ABBV) said Friday they are in an exclusive, global strategic collaboration and option agreement to develop and commercialize treatments for Parkinson's disease and other diseases.

Voyager shares surged 21% premarket.

Voyager will receive $65 million cash upfront and can earn up to $245 million in preclinical and Phase 1 option payments. Voyager also can receive up to an additional $728 million in potential development and regulatory milestone payments for each alpha-synuclein vectorized antibody compound. Voyager is eligible for tiered royalties and may also earn up to $500 million in commercial milestones.

Voyager will perform research and preclinical development work, after which AbbVie may select vectorized antibodies to advance into studies and clinical development. Voyager will be responsible for the research, IND-enabling and Phase 1 clinical activities and costs. After Phase 1 clinical development, AbbVie can option to license the program for further clinical development and global commercialization.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

February 22, 2019 08:35 ET (13:35 GMT)

Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2024 to Sep 2024